[1] Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety[J]. Proc Natl Acad Sci USA, 1996, 93(21): 11341-11348.
[2] Qian C, Chen S, Ding P, et al. The immune response of a recombinant fowlpox virus coexpressing the HA gene of the H5N1 highly pathogenic avian influenza virus and chicken interleukin 6 gene in ducks[J]. Vaccine, 2012, 30(44): 6279-6286.
[3] Amann R, Rohde J, Wulle U, et al. A new rabies vaccine based on a recombinant ORF virus (parapoxvirus) expressing the rabies virus glycoprotein[J]. J Virol, 2013, 87(3): 1618-1630.
[4] Chen W, Hu S, Qu L, et al. A goat poxvirus-vectored peste-des-petits-ruminants vaccine induces long-lasting neutralization antibody to high levels in goats and sheep[J]. Vaccine, 2010, 28(30): 4742-4750.
[5] Smith G L, Moss B. Infectious poxvirus vectors have capacity for at least 25 000 base pairs of foreign DNA[J]. Gene, 1983, 25(1): 21-28.
[6] 赵银龙, 吴国华, 朱海霞, 等. 山羊痘病毒A6L基因的克隆及序列分析[J]. 中国畜牧兽医, 2015,42(8): 1973-1978.
[7] Shen Y J, Shephard E, Douglass N, et al. A novel candidate HIV vaccine vector based on the replication deficient Capripoxvirus, Lumpy skin disease virus (LSDV)[J]. Virol J, 2011, 8: 265.
[8] Yuan M, Zhang W, Wang J, et al. Efficiently editing the vaccinia virus genome by using the CRISPR-Cas9 system[J]. J Virol, 2015, 89(9): 5176-5179.
[9] Buller R M, Smith G L, Cremer K, et al. Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype[J]. Nature, 1985, 317(6040): 813-815.
[10] Burgers W A, Ginbot Z, Shen Y J, et al. The novel capripoxvirus vector lumpy skin disease virus efficiently boosts modified vaccinia Ankara human immunodeficiency virus responses in rhesus macaques[J]. J Gen Virol, 2014, 95(10): 2267-2272.
[11] 李继东, 蒙学莲, 朱学亮, 等. 小反刍兽疫病毒H基因或F基因重组山羊痘病毒活载体疫苗的研究[J]. 中国兽医科学, 2015,45(2): 111-117.
[12] 李继东, 朱学亮, 李 辉, 等. 启动子p7.5/p11在山羊痘病毒和羊口疮病毒中的启动功能验证[J]. 中国预防兽医学报, 2014,36(11): 829-833.
[13] 李有文, 魏 风, 郭志儒, 等. 山羊痘病毒疫苗株TK基因的克隆与序列分析[J]. 西北农业学报, 2010,19(1): 1-5.
[14] Taylor G, Stott E J, Wertz G, et al. Comparison of the virulence of wild-type thymidine kinase (tk)- deficient and tk+ phenotypes of vaccinia virus recombinants after intranasal inoculation of mice[J]. J Gen Virol, 1991, 72(1): 125-130.
[15] Sebastian S, Gilbert S C. Recombinant modified vaccinia virus Ankara-based malaria vaccines[J]. Expert Rev Vaccines, 2016, 15(1): 91-103.
[16] Caufour P, Rufael T, Lamien C E, et al. Protective efficacy of a single immunization with capripoxvirus-vectored recombinant peste des petits ruminants vaccines in presence of pre-existing immunity[J]. Vaccine, 2014, 32(30): 3772-3779.
[17] Gari G, Abie G, Gizaw D, et al. Evaluation of the safety, immunogenicity and efficacy of three capripoxvirus vaccine strains against lumpy skin disease virus[J]. Vaccine, 2015, 33(28): 3256-3261.
[18] Backes S, Jager C, Dembek C J, et al. Protein-prime/modified vaccinia virus Ankara vector-boost vaccination overcomes tolerance in high-antigenemic HBV-transgenic mice[J]. Vaccine, 2016, 34(7): 923-932.
[19] 郑 敏, 梁 晟, 郑彦梓, 等. TK基因重组缺陷山羊痘病毒构建及其生物学特性鉴定[J]. 南方农业学报, 2013,44(9): 1552-1557.
[20] Boshra H, Cao J, Babiuk S. Generation of recombinant capripoxvirus vectors for vaccines and gene knockout function studies[J]. Methods Mol Biol, 2016, 1349: 151-161.
[21] Gelaye E, Lamien C E, Silber R, et al. Development of a cost-effective method for capripoxvirus genotyping using snapback primer and dsDNA intercalating dye[J]. PLoS One, 2013, 8(10): e75971. |